| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
180,310,000 |
| Market
Cap: |
41.24(B) |
| Last
Volume: |
799,597 |
Avg
Vol: |
864,930 |
| 52
Week Range: |
$191.51 - $228.9 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Seagen is a biotechnology company that develops and commercializes targeted therapies to treat cancer. Co. is commercializing ADCETRIS®, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas, PADCEV®, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers, TIVDAK™, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers, and TUKYSA®, or tucatinib, for treatment of certain metastatic HER2-positive breast cancers. Co. is also developing a pipeline of therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
39,326 |
449,967 |
| Total Sell Value |
$0 |
$0 |
$8,245,949 |
$81,866,696 |
| Total People Sold |
0 |
0 |
7 |
8 |
| Total Sell Transactions |
0 |
0 |
18 |
69 |
| End Date |
2024-03-31 |
2023-12-29 |
2023-06-30 |
2022-06-30 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Siegall Clay B |
President and CEO |
• • – |
2007-08-20 |
4 |
OE |
$3.00 |
$213,900 |
D/D |
71,300 |
1,088,000 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2007-08-17 |
4 |
S |
$11.16 |
$353,823 |
D/D |
(31,668) |
1,086,500 |
|
- |
|
| Siegall Clay B |
President and CEO |
• • – |
2007-08-17 |
4 |
OE |
$3.00 |
$95,004 |
D/D |
31,668 |
1,098,668 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-07-09 |
4 |
A |
$0.00 |
$0 |
I/I |
2,101,300 |
3,254,517 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2007-07-09 |
4 |
A |
$0.00 |
$0 |
I/I |
4,485,000 |
1,058,640 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-07-09 |
4 |
A |
$0.00 |
$0 |
I/I |
1,916,150 |
5,390,969 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-07-09 |
4 |
A |
$0.00 |
$0 |
I/I |
466,050 |
471,007 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-07-09 |
4 |
A |
$0.00 |
$0 |
I/I |
316,500 |
320,498 |
|
- |
|
| Trailsmith Pamela A |
Chief Scientific Officer |
• – – |
2007-05-17 |
4 |
S |
$10.20 |
$612,485 |
D/D |
(59,891) |
6,940 |
|
- |
|
| Trailsmith Pamela A |
Chief Scientific Officer |
• – – |
2007-05-17 |
4 |
OE |
$4.18 |
$250,344 |
D/D |
59,891 |
16,740 |
|
- |
|
| Rosenberg Morris |
Sr. VP, Development |
• – – |
2007-05-17 |
4 |
S |
$10.30 |
$257,990 |
D/D |
(25,000) |
0 |
|
- |
|
| Rosenberg Morris |
Sr. VP, Development |
• – – |
2007-05-17 |
4 |
OE |
$6.72 |
$168,000 |
D/D |
25,000 |
3,500 |
|
- |
|
| Rosenberg Morris |
Sr. VP, Development |
• – – |
2007-04-27 |
4 |
S |
$9.53 |
$238,500 |
D/D |
(25,000) |
0 |
|
- |
|
| Rosenberg Morris |
Sr. VP, Development |
• – – |
2007-04-27 |
4 |
OE |
$6.72 |
$168,000 |
D/D |
25,000 |
10,000 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
S |
$8.72 |
$170,572 |
I/I |
(19,561) |
75,598 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4/A |
S |
$8.76 |
$171,354 |
I/I |
(19,561) |
75,598 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
S |
$8.76 |
$901,711 |
I/I |
(102,935) |
3,998 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
A |
$0.00 |
$0 |
I/I |
80,000 |
106,933 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
S |
$8.72 |
$8,718,099 |
I/I |
(999,782) |
1,153,217 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
A |
$0.00 |
$0 |
I/I |
617,000 |
2,152,999 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
S |
$8.72 |
$1,307,390 |
I/I |
(149,930) |
4,957 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
A |
$0.00 |
$0 |
I/I |
78,000 |
154,887 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
S |
$8.72 |
$13,950,186 |
I/I |
(1,599,792) |
3,474,819 |
|
- |
|
| Baker Felix |
Director |
– • • |
2007-02-14 |
4 |
A |
$0.00 |
$0 |
I/I |
925,000 |
5,074,611 |
|
- |
|
| Akkaraju Srinivas |
Director |
– • – |
2007-02-09 |
4 |
S |
$8.57 |
$17,268,550 |
I/I |
(2,015,000) |
0 |
|
- |
|
1805 Records found
|
|
Page 60 of 73 |
|
|
